Loading clinical trials...
Loading clinical trials...
Maternal and Postnatal Outcomes Study (MOS) A Worldwide Decentralized Observational Registry to Evaluate the Safety in Women With Fabry Disease and Their Infants Exposed to Elfabrio® (Pegunigalsidase Alfa-iwxj/Pegunigalsidase Alfa) During Pregnancy and/or Lactation
Conditions
Interventions
Not applicable- observational study
Locations
5
United States
No physical study sites - Decentralized, web-based registry
Washington D.C., District of Columbia, United States
No physical study sites - Decentralized, web-based registry
Berlin, Germany
No physical study sites - Decentralized, web-based registry
Rome, Italy
No physical study sites - Decentralized, web-based registry
Madrid, Spain
No physical study sites - Decentralized, web-based registry
London, United Kingdom
Start Date
May 23, 2025
Primary Completion Date
December 1, 2034
Completion Date
December 1, 2034
Last Updated
March 19, 2026
NCT07197892
NCT07437248
NCT06968026
NCT06965530
NCT06312644
NCT07525193
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions